# Health Care and Competition Law and Policy in Ireland 

## Presentation to FTC/DoJ

Declan Purcell, Member

Competition Authority, Ireland 30 th September 2003

## Presentation Outline

- Irish Competition Law and the Competition Authority
- Overview of the Irish Health Sector
- Public Health System
- Private Health Sector
- Selected competition issues in the medical subsectors
- Health Insurance
- The Hospital Sector
- The Pharmaceutical Sector
- Professional Regulation
- Concluding Comments - Health Competition Policy Going Forward


## Irish Competition Law

- Competition legislation
- Competition Authority functions:
- Enforcement: Cartels and Abuse of Dominance
- Merger Control
- Advocacy
- Advocacy - obligations/powers:
- Advise Ministers and governmental bodies on new and existing legislation
- Conduct studies of markets and sectors
- General advocacy efforts


## Overview of the Irish Health Sector

- Economic Importance:
- 6.5\% of GDP or $\$ 10.5$ billion in 2001 (and climbing)
- $76 \%$ of this came from public sources
- $21.5 \%$ of all public expenditure (and climbing) or $€ 2,300$ per capita
- Public-Private Mix:
- $31 \%$ of population have complete public cover (or entitlement)
- Remaining 69\% of population have limited subsidised cover (drugs and hospital stays)
- But entitlement does not equate to timely access - long waiting lists


## Irish Health Sector - Public

- Fragmented and old organisation:
- Department of Health and Children
- 10 Regional State Health Boards
- Multiple semi-autonomous health agencies
- Funding:
- Predominantly through general taxation (more than 80\%)
- Also, through out-of-pocket expenses
- Revenue from public hospital beds used by private patients
- Performance and value for money:
- Funding has increased by $125 \%$ over the last five years little perceived improvement with waiting lists still long
- Many reports on the issue
- Consensus is that radical overhaul is required


## The Irish Health Sector - Private

- Markets exist in
- GP medical and specialist services
- Pharmaceuticals
- Hospital care
- Private Health Insurance
- $47 \%$ of the population have private cover
- State-owned VHI has approximately 87\% market share
- BUPA Ireland has approximately $13 \%$
- Two-tierism - private insurance as a queue-jumping mechanism


## Perceived Problems

- At a general level, questions about:
- Waiting lists
- Medical inflation
- Extra-territorial purchase of public health services
- Inflexible health system
- The role of the State in regulation, supply and demand
- At the individual market level there are questions about:
- Hospital capacity
- Competition in primary care
- Prices for specific services
- Medical professions
- Pharmacy/pharmaceutical issues
- Risk equalisation


## Health Insurance

- Only two firms:
- VHI (state owned) had effective statutory monopoly until 1994.
- BUPA Ireland, the only new entrant (in 1996), has approximately $13 \%$ market share.
- Competition perceived to be weak - not surprising.
- Likely barriers to entry:
- Community rating and Risk Equalisation (RE).
- Ministerial involvement and uncertainty about RE.


## Health Insurance (contd)

- BUPA in EU courts on grounds that Risk Equalisation is a State Aid to VHI
- Study of Competition by Health Insurance Authority is ongoing
- Privatisation of VHI on/off the table - too big to privatise as a single company?


## The Hospital Sector

- The private hospital sector consists of both private and 'public' elements:
- $20 \%$ of public hospitals beds have been designated for use by private patients, but this portion is regularly exceeded
- About $15 \%$ of total hospital bed capacity is privately owned
- Thus, about a third of hospital beds are available for private use
- Public beds available for private use are charged at a rate below economic cost
- Implication - the public hospital sector has probably inhibited the growth of the private hospital sector


## The Pharmaceutical Sector

- Retail pharmacy unconcentrated, but heavily regulated - large rents available
- Major underprovision in Pharmacy education
- Retail Pharmacy is highly regulated:
- Restrictions on establishment, e.g., new pharmacies could not open near existing ones (removed in 2002)
- Restrictions on overseas graduates
- New restrictions on the establishment of chains mooted
- Price Regulation at Import/Wholesale/Level - prices set by agreement with the Department of Health
- Retail Prices high - uniform 50\% retail margin for private prescriptions


## Professional Regulation

- Enforcement difficult:
- Many restrictions bound up in public regulations.
- 3 basic restriction types -
- Entry
- Behaviour
- Organisational Form
- Major Role for Advocacy - large-scale Competition Study of 8 professions including medical practitioners (MD), optometrists (O) and dentists (D).
- Proportionality the key


## Professional Regulation (contd.)

- Preliminary Study Findings:
- Restrictions on entry, e.g., through education (MD, $\mathrm{D}, \mathrm{O}$ ), transferring from other countries (MD \& D), the manner in which posts within the public system are filled (MD), demarcation (D)
- Restrictions on advertising, e.g., type of information and size or none allowed at all (MD, D, O)
- Restrictions of organisational form, e.g., no limited liability (MD), not within corporate structures (D).


## Health Competition Policy Going Forward

- Competition in Health care often perceived as not relevant:
- In principle, because it’s sacrosanct
- In practice because markets often don't exist
- In law because public regulation prevents it
- Implication - much greater role for Advocacy, for some time to come
- Authority plans to stimulate debate on healthcare and competition through public consultation process


## Specific Issues

- Collective action
- Pharmacy/Pharmaceuticals
- Competition and the Professions
- Health insurance
- Out-sourcing of public services to private providers


## Conclusion

- National systems may differ..........
- ......but the problems are familiar.


# Health Care and Competition Law and Policy in Ireland 

## Presentation to FTC/DoJ

Declan Purcell, Member

Competition Authority, Ireland 30 th September 2003

